Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026GlobeNewsWire • Thursday
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • Wednesday
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/09/26
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?Zacks Investment Research • 09/18/26
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE DrugZacks Investment Research • 09/09/26
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)GlobeNewsWire • 09/08/26
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionGlobeNewsWire • 09/04/26
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/04/26
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron RevenuesZacks Investment Research • 08/07/26
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/26
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 08/06/26
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 07/30/26
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 07/09/26
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR TherapeuticsThe Motley Fool • 07/08/26